Research Library

Emerging clinical evidence and case series describing the use of intranasal VIP in patients with Long COVID, post-viral dysautonomia, and MCAS. Reports significant improvements in fatigue, autonomic function, and inflammatory biomarkers.

Landmark SELECT trial demonstrating that semaglutide 2.4mg reduced major adverse cardiovascular events by 20% in overweight/obese patients without diabetes.

Pivotal STEP 1 trial showing that once-weekly subcutaneous semaglutide 2.4 mg produced an average weight loss of 14.9% vs 2.4% with placebo in adults with obesity.

Pivotal Phase 3 RECONNECT trial that led to FDA approval of bremelanotide for hypoactive sexual desire disorder in premenopausal women.

Study demonstrating VIP's potent mast cell stabilizing effects, with implications for MCAS (Mast Cell Activation Syndrome) and allergic conditions. VIP was shown to dose-dependently inhibit IgE-mediated mast cell degranulation.

Review of GHK-Cu's gene expression effects using the Broad Institute Connectivity Map, revealing regulation of approximately 4,000 human genes involved in antioxidant defense, tissue remodeling, and stem cell biology.

Study demonstrating that BPC-157 upregulates growth hormone receptor expression in tendon fibroblasts, promoting tendon healing through enhanced cellular proliferation and migration.

Comprehensive review of BPC-157's effects on inflammatory bowel disease, detailing its cytoprotective mechanisms across the GI tract including protection against NSAID-induced lesions, alcohol damage, and various experimental colitis models.

Study demonstrating LL-37's potent antimicrobial activity against methicillin-resistant Staphylococcus aureus (MRSA) strains through membrane disruption and biofilm prevention.

Randomized, double-blind trial investigating tesamorelin's effects on cognitive function in adults aged 60+ with mild cognitive impairment (MCI) or normal cognition. Demonstrated that GHRH restoration via tesamorelin significantly improved verbal memory and executive function.

Comprehensive review of Selank's pharmacological profile covering its anxiolytic, nootropic, and immunomodulatory mechanisms and clinical applications.

The FDA approved tesamorelin (brand name Egrifta) on November 10, 2010, making it the first and only FDA-approved GHRH analog for the treatment of HIV-associated lipodystrophy — specifically excess visceral (abdominal) fat in HIV-infected adults on antiretroviral therapy. This marked a milestone as the first peptide of its class to receive full regulatory approval.

52-week extension study evaluating sustained efficacy and long-term safety of tesamorelin in HIV lipodystrophy patients following the pivotal Phase 3 trials. Supported continued FDA-approved use and long-term tolerability profile.

Meta-analysis of clinical trials evaluating Thymosin Alpha-1 for chronic Hepatitis B treatment, demonstrating significant improvements in virological and biochemical response rates.

A landmark Phase 3 randomized, double-blind, placebo-controlled trial demonstrating that tesamorelin (2 mg/day SC) significantly reduced visceral adipose tissue (VAT) in HIV-infected patients with lipodystrophy. This study formed the primary basis for FDA approval of Egrifta (tesamorelin) in 2010.

Comprehensive review of VIP's role as an endogenous anti-inflammatory neuropeptide, detailing its mechanisms of immune regulation, cytokine suppression, and potential therapeutic applications in autoimmune and inflammatory diseases.

First-in-human clinical trial of CJC-1295 DAC showing sustained elevation of GH and IGF-1 levels for up to 14 days after a single subcutaneous injection.

Clinical trial evaluating Semax in patients with acute ischemic stroke, showing improved cognitive recovery and neurological outcomes compared to standard treatment.

Landmark study showing that Thymosin Beta 4 promotes cardiac repair following myocardial infarction by activating cardiac progenitor cells and promoting neovascularization.

Study demonstrating that Epithalon activates telomerase in human somatic cells, leading to telomere elongation and extended replicative lifespan of fibroblast cultures.

Characterization of Ipamorelin as the first GH secretagogue that releases GH with efficacy comparable to GHRP-6 but without affecting ACTH, cortisol, prolactin, FSH, LH, or TSH.